» Articles » PMID: 28679655

Marketing of Unproven Stem Cell-based Interventions: A Call to Action

Abstract

Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.

Citing Articles

Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.

Ogbogu U, Case N F1000Res. 2024; 12:1165.

PMID: 39430869 PMC: 11489844. DOI: 10.12688/f1000research.141002.2.


Towards stem cell therapies for hearing loss: awareness and perspectives of Australian audiologists and their patients.

Iem D, Carney G, Munsie M, Nayagam B Regen Med. 2024; 19(9-10):483-496.

PMID: 39378073 PMC: 11487944. DOI: 10.1080/17460751.2024.2402650.


The evolution and ongoing challenge of unproven cell-based interventions.

Brinsfield T, Pinson N, Levine A Stem Cells Transl Med. 2024; 13(9):851-858.

PMID: 39045646 PMC: 11386208. DOI: 10.1093/stcltm/szae050.


Opinion: Patient reported motivations for seeking stem cell therapy and considerations for counseling.

Arthurs J, Master Z, Shapiro S J Orthop Orthop Surg. 2024; 3(3):1-3.

PMID: 38989057 PMC: 11235191. DOI: 10.29245/2767-5130/2022/3.1162.


Compliance with requirements for registration and reporting of results in trials of mesenchymal stromal cells for musculoskeletal disorders: a systematic review.

Holtedahl R, Brox J BMJ Open. 2024; 14(6):e081343.

PMID: 38925685 PMC: 11202644. DOI: 10.1136/bmjopen-2023-081343.